MagnaPharm and Dr. Wolff-Group enter into an exclusive partnership for the distribution and promotion of Dr. Wolff brands in Poland
May 26th, 2020
MagnaPharm and Dr. Wolff-Group have entered into an Exclusive Distribution and Promotion Agreement of Dr. Wolff's brands in the territory of Poland. Partnership is covering distribution and promotion of brands Arilin Rapid and Vagisan. The brand Vagisan® comprises medicinal products, medical devices and cosmetics to support women in their wellbeing and the maintenance of the health state of their intimate region. Vagisan is the market leader for intimate care in Germany and its products are recognized by their high quality and efficacy. Arilin Rapid is high quality metronidazole short-term treatment with improved efficacy and tolerability. Dr. Wolff with its women healthcare portfolio is established as partner of gynecologists community in Germany and other markets of Europe, well recognized for efficacy and high quality of its products. MagnaPharm is one of leading players in both, Rx and OTC segments of pharmaceutical market in CEE and offers an excellent platform to further grow Dr. Wolff women healthcare franchise.
“We are excited and proud to announce our partnership with Dr. Wolff-Group. For more than a decade we are very successful in marketing of unique Rx and premium OTC pharmaceuticals and medical devices in Poland. Women healthcare is one of our key therapeutic fields we are developing strategically in MagnaPharm geography. Dr. Wolff's efficient and high-quality brands and its strong marketing expertise in women healthcare perfectly fits with our existing portfolio structure and is enabling us to further expand our presence in women healthcare in Poland. We believe we are creating a great base to further growth of existing sales of Dr. Wolff brands and to efficiently launch other Dr. Wolff brands in Poland. The cooperation will help us to maintain and grow MagnaPharm's strong presence in Polish pharmaceutical market. We look forward to working with Dr. Wolff in achieving our milestones and increasing standards of care in women healthcare.”
Karol Michalak, CEO MagnaPharm